Appropriate use of triazolam in elderly patients considering a quantitative benefit-risk assessment based on the pharmacokinetic-pharmacodynamic modeling and simulation approach supported by real-world data

Akira Okada,Shoji Sera,Naomi Nagai
DOI: https://doi.org/10.1186/s40360-024-00777-z
2024-09-04
BMC Pharmacology and Toxicology
Abstract:Triazolam is a typical drug commonly used in the elderly; however, there have been concerns about its adverse events resulting from age-related changes in physiological function and drug interactions with concomitant drugs. Thus, updated information contributing to the appropriate use based on the latest pharmacokinetic and post-marketing surveillance methods is needed. In this study, we evaluated the appropriate use of triazolam in the elderly by integrating real-world data with a modeling and simulation approach.
pharmacology & pharmacy,toxicology
What problem does this paper attempt to address?